Testing MIL116 in healthy people and those with IgA Nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called MIL116 for IgA Nephropathy. First, healthy volunteers will test the drug's safety, then people with IgA Nephropathy will see if it can help reduce protein in their urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For healthy volunteers: You must be 18 to 55 years old, weigh at least 110 pounds, and have a BMI between 19 and 32.
- For people with IgA Nephropathy: You must have a kidney biopsy confirming the disease and have protein in your urine (at least 0.75 grams per day).
- You must be on a stable dose of certain blood pressure medications (ACE inhibitors or ARBs) for a while before joining.
- You cannot have received certain immune-suppressing drugs (like rituximab or cyclophosphamide) in the last 3 to 6 months.
- You cannot have very high protein in your urine (over 3.5 grams per day) or other severe kidney conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests a new medicine called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and helps reduce protein in the urine, which is a sign of kidney damage.
This trial tests a new medicine (FXS6837) for people with IgA nephropathy (a kidney disease that causes protein in the urine and can lead to kidney damage). The goal is to see if it can reduce protein loss and protect kidney function.
This study tests a new drug, MY008211A, for people with a type of kidney disease called IgA nephropathy. The goal is to see if it can reduce protein in the urine and help protect kidney function. You must have had a kidney biopsy confirming the diagnosis and be on stable standard care.
Hear when a new Immunoglobulin A Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.